Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs Inc (KNW) pioneers non-invasive diagnostic technologies using its patented Bio-RFID and ChromaID systems, transforming traditional medical testing methods. This page serves as the definitive source for verified updates on the company's regulatory progress, clinical validations, and strategic partnerships in the healthtech sector.
Access real-time announcements about wearable device developments, FDA submissions, and peer-reviewed study results. Investors and healthcare professionals will find curated updates on product commercialization timelines, intellectual property expansions, and collaborative research initiatives.
Key content includes earnings call summaries, technology licensing agreements, and analysis of clinical trial outcomes. All materials adhere to journalistic standards for accuracy, providing actionable insights without speculative commentary.
Bookmark this page to monitor Know Labs' advancements in replacing invasive blood tests with electromagnetic-based solutions, including their flagship non-invasive glucose monitor currently under regulatory review.
Know Labs (NYSE American: KNW) has appointed Chris Somogyi as President, International. Somogyi, with over 40 years of experience in commercializing innovation, will lead the 'Skunkworks' Program and global patent licensing efforts. His focus will be on leveraging Know Labs' IP portfolio of over 300 patents for diverse applications, including the KnowU™ continuous glucose monitor. He aims to drive global revenue, particularly in regions with high diabetes incidence such as Asia, Africa, South America, and the Middle East. Somogyi's extensive background includes roles at Stanford, SRI International, Xerox PARC, and Intellectual Ventures. CEO Ron Erickson expressed confidence in Somogyi's capability to enhance the company's strategic initiatives and revenue generation efforts.
Know Labs (NYSE American: KNW) reported Q2 FY 2024 results, showing an operating loss of $4.73 million, slightly better than the $4.81 million loss in Q2 FY 2023. EPS improved 30% to a loss of $0.07 from $0.10. R&D expenses dropped 15.1% to $2.18 million, while SG&A expenses increased 13.7% to $2.55 million. Cash and cash equivalents fell to $4.71 million from $8.02 million, and net cash used in operations rose to $7.05 million. Shareholder equity turned negative at -$1.75 million. The company announced an $18 million S-3 shelf registration for liquidity and plans to raise funds through equity and convertible debt.
Know Labs, Inc. (KNW) has been chosen to present an oral abstract at the 2024 American Association of Clinical Endocrinology Annual Meeting. The abstract, titled 'Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes Management Using a Radiofrequency Sensor and Machine Learning,' will showcase the accuracy and medical application of its proprietary sensor. The company will continue deploying its KnowU™ wearable continuous glucose monitor in large-scale clinical trials toward FDA clearance, focusing on performance in real-world environments and extreme glycemic ranges.
Know Labs, Inc. (NYSE American: KNW) will host a webcast on May 15, 2024, to review Q2 FY 2024 results. The company is focused on non-invasive medical diagnostic technology, including a continuous blood glucose monitoring device.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
